Alnylam Pharmaceuticals, Inc.
SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT

Last updated:

Abstract:

The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpina1 gene, and methods of using such dsRNA compositions to inhibit expression of Serpina1.

Status:
Application
Type:

Utility

Filling date:

5 Oct 2021

Issue date:

19 May 2022